Sangamo Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and a Favorable Safety Profile

Uncategorized

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 1, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Jefferies Healthcare Conference Date: Thursday, June 9 at 9:00 a.m.